Cho Hyeyoun, Park Sanghyo, Park Jun Young, Hwang Yoonho, Kang Won Jun, Key Jaehong
Department of Biomedical Engineering, Yonsei University, Wonju, 26493, Republic of Korea.
Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
Mater Today Bio. 2025 Aug 9;34:102189. doi: 10.1016/j.mtbio.2025.102189. eCollection 2025 Oct.
Silk proteins, such as silk sericin (SS) and silk fibroin (SF), have been shown to exhibit excellent biocompatibility, biodegradability, and low immunogenicity as drug delivery carriers. SS possesses antioxidant and anticancer adjuvant properties, whereas SF provides mechanical strength and structural stability, marking them as optimal materials for drug delivery systems. In this study, 3 μm discoidal silk protein particles (DSPs) based on silk sericin/silk fibroin (SS/SF) composites were developed for the loading of docetaxel (DTX). A comprehensive analysis was conducted to assess the morphological characteristics, particle size, zeta potential, drug loading content, and colloidal stability of the particles. studies utilizing human-derived non-small cell lung cancer (A549) and mouse-derived squamous cell carcinoma (SCC7) cell lines revealed that DTX-SS/SF-DSPs exhibited superior anticancer activity compared to both free DTX and DTX-SF-DSPs. biodistribution studies revealed that DTX-SS/SF-DSPs effectively accumulated in the lungs, with minimal accumulation in non-target organs, including the liver and kidneys. Anticancer efficacy evaluations showed a significant reduction in the number of tumor nodules and improvement in survival rates. Furthermore, histopathological analysis confirmed reduced inflammatory responses and the absence of major organ toxicity, demonstrating excellent biocompatibility. In conclusion, SS/SF-DSPs are a promising drug delivery system that can improve the therapeutic efficacy of anticancer drugs with minimal side effects, which can present a new paradigm in lung cancer treatment.
丝蛋白，如丝胶蛋白（SS）和丝素蛋白（SF），已被证明作为药物递送载体具有优异的生物相容性、生物降解性和低免疫原性。SS具有抗氧化和抗癌佐剂特性，而SF提供机械强度和结构稳定性，使其成为药物递送系统的理想材料。在本研究中，开发了基于丝胶蛋白/丝素蛋白（SS/SF）复合材料的3μm盘状丝蛋白颗粒（DSPs）用于多西他赛（DTX）的负载。对颗粒的形态特征、粒径、zeta电位、载药量和胶体稳定性进行了全面分析。利用人源非小细胞肺癌（A549）和小鼠源鳞状细胞癌（SCC7）细胞系的研究表明，与游离DTX和DTX-SF-DSPs相比，DTX-SS/SF-DSPs表现出优异的抗癌活性。生物分布研究表明，DTX-SS/SF-DSPs有效地在肺部积累，在包括肝脏和肾脏在内的非靶器官中积累最少。抗癌疗效评估显示肿瘤结节数量显著减少，生存率提高。此外，组织病理学分析证实炎症反应减轻且无主要器官毒性，表明具有优异的生物相容性。总之，SS/SF-DSPs是一种有前途的药物递送系统，可在最小副作用的情况下提高抗癌药物的治疗效果，这可为肺癌治疗提供一种新的范例。
